Endocrinology

Carel le Roux, PhD, MSC, discusses the investigative dual GLP-1/glucagon agonist’s weight loss efficacy in patients with obesity and overweight without T2D.

This episode covers key trial results and presentations to keep an eye on as ADA 2026 approaches.

Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Schatz highlights the current limitations to a broader integration of T1D screening and suggests methods to circumvent these blockages.

The FDA has cleared the EndoTool IV Cloud for hospital IV insulin dosing support, expanding Glooko’s inpatient platform via the 510(k) pathway.

The NDA submission follows positive results from the CALIBRATE phase 3 trial, which evaluated encaleret versus standard-of-care in adults with ADH1.

This episode covers recent advancements in treating type 1 diabetes, including the Tandem AID system for pregnant women and teplizumab for adolescents.

The new recommendations outline glucocorticoid tapering strategies for adults and children with classic CAH after starting crinecerfont.

Catch up on key clinician insights, major FDA decisions, groundbreaking trial results, and more.

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

Stay updated with the latest healthcare breakthroughs, including notable FDA approvals and filings, in this week’s essential news roundup.

Sood shares her thoughts on the recent announcement by the FDA, limiting pharmacies’ ability to compound semaglutide, tirzepatide, and liraglutide from bulk substances.

Sadhu provides an update on the state of the stem cell and islet cell therapy landscapes, highlighting encouraging developments in insulin independence.

Shahla discusses a recent real-world study analyzing the clinical outcomes of patients prescribed paltusotine after its September 2025 approval.

Silverstein addresses a secondary analysis of the GRACE trial, highlighting relacorilant’s efficacy in reducing cortisol in patients taking GLP-1 RAs.

Joshi explains the narrow window of optimal iodine levels, highlighting the risk posed by supplements and iodized salt in tipping the scales toward health risks.

Isaacs covers the range of AID devices currently available and approved for T2D, providing suggestions for implementation and continuous glycated hemoglobin monitoring.

Viral Shah, MD, joins the show to break down his AACE 2026 presentation on the benefits of using GLP-1 RAs in patients with T1D.

FDA cleared Control-IQ+ for pregnancy in type 1 diabetes, expanding automated insulin delivery options during gestation.

Elizabeth Bauer, MD, joins the show to discuss her AACE 2026 presentation on key updates in obesity management and nutrition.

Auchus discusses the 2-year results from CAHtalyst Adult, highlighting the substantial retention rates over the open-label extension period.

Isaacs explains how prediabetes care is shifting toward early intervention, risk stratification, and prevention of cardiometabolic disease, not just progression to diabetes.

Hamidi reviews 2-year CAHtalyst data showing crinecerfont enabled sustained glucocorticoid reductions to physiologic range in adults with classic congenital adrenal hyperplasia.

Linda DiMeglio, MD, MPH, joins the show to discuss the growing movement towards screening and testing for T1D at an early stage.